27/08/2020
CoSec helped Immunic Therapeutics, a Munich-based clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies, to expand into the Australian market and conduct clinical trials here. With a recent capital raising on the NASDAQ of $103.5 million, Immunic is an excellent example of the opportunities available to European life sciences companies seeking to fast track their clinical trial program.
Read the case study here.